GSK: ViiV Heathcare to supply 2M doses of cabotegravir

(CercleFinance.com) - GSK has announced that ViiV Healthcare, its specialist HIV business, has pledged to supply at least two million doses of long-acting cabotegravir (CAB LA) for HIV pre-exposure prophylaxis (PrEP) to low- and middle-income countries (LMICs) in 2025-2026.


This new promise will triple availability compared with 2024 to meet growing demand, particularly in sub-Saharan Africa.

CAB LA, the first injectable long-acting PrEP, is distributed at cost price in low-income countries via partners such as PEPFAR and the Global Fund.

Copyright (c) 2024 CercleFinance.com. All rights reserved.